A Phase 4 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 81 sites in 10 countries. Open to participants aged 41 Years to 84 Years. Per ClinicalTrials.gov, last updated 2019-08-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 15th largest by enrollment, is one of 8 that started in 2015, is one of 11 in phase 4, and was the 47th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 41 Years to 84 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 776 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 23rd largest by enrollment of the 116 interventional ones that give a count, is one of 10 that started in 2015, is one of 24 in phase 4, and was the 101st registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe. The efficacy and safety of the drug was tested for twice daily dosing against once daily dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.
Drug: NVA237 · Drug: Salbutamol
Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.
Drug: NVA237 · Drug: Placebo · Drug: Salbutamol
NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
Also known as: glycopyrronioum bromide
Placebo to NVA237
All patients received salbutamol (100 μg) as only rescue medication
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1 at Week 12. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.
Time frame: Baseline, Week 12
Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 12
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 12 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.
Time frame: Baseline, 0-12 hour, 0-24 hour , 12-24 hour post dose at Week 12
Change From Baseline in Area Under The Curve (AUC 0-12 Hour) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at Day 1
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for 0-12 hour, post dosing at Day 1 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.
Time frame: Baseline, 0-12 hour post dose at Day 1
Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 26
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 26 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.
Time frame: Baseline, 0-12 hour, 0-24 hour , 12-24 hour post dose at Week 26
Change From Baseline in Total St. George's Respiratory Questionnaire (SGRQ) Score at Week 12 and Week 26
The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: * Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity * Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness * Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. Higher values corresponded to greater impairment of health status.
Time frame: Baseline, 12 Weeks, 26 Weeks
Percentage of Patients With a Clinically Significant Improvement in St George Respiratory Questionnaire at Week 12 and Week 26
The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: * Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity * Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness * Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. A clinically significant improvement is defined as ≥ 4 unit improvement from baseline score (a decrease of ≥ 4).
Time frame: Baseline, 12 Weeks, 26 Weeks
Change From Baseline in Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26
Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score.
Time frame: Baseline, 12 Weeks, 26 Weeks
Percentage of Patients With a Clinically Important Improvement on Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26
Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. Clinically important improvement indicates ≥ 1 unit in the TDI focal score at Weeks 12 and 26 in comparison to BDI focal score (an increase of ≥ 1).
Time frame: Baseline, 12 Weeks, 26 Weeks
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 26
Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.
Time frame: Baseline, Day 1, Week 26
Change From Baseline in Forced Vital Capacity (FVC) at Individual Timepoints at Week 26
Mixed model for repeated measures was used to analyze change from baseline in FVC. Baseline FVC is defined as the average of the -45 min and -15 min FVC values taken on Day 1 prior to first dose.
Time frame: Baseline, Week 26 (Day 183-184)
Change From Baseline in Inspiratory Capacity (IC) at Individual Timepoints at Week 26
Mixed model for repeated measures was used to analyze change from baseline in IC.
Time frame: Baseline, Week 26 (Day 183-184)
Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Individual Timepoints at Week 26
Mixed model for repeated measures was used to analyze change from baseline in FEV1. Baseline FEV1 is defined as the average of the -45 min and -15 min FEV1 values taken on Day 1 prior to first dose.
Time frame: Baseline, Week 26 (Day 183-184)
Change From Baseline in the Percentage of Days With no Rescue Medication Use Over the 26 Weeks
Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. change from baseline in percentage of days without rescue medication usage over 26 weeks was analyzed.
Time frame: Baseline, 26 Weeks
Change From Baseline in Mean Daily COPD Symptom Score at Week 26
Patients reported symptoms by using an electronic diary. The mean daily total symptom score, the mean morning symptom score and the mean evening symptom score were calculated for each patient over 26 weeks. Each symptom measured in a numeric rating scale of 0-10; 0 indicates no symptom and 10 indicates severe symptom. 0 is no waking due to symptoms, 1 woke up once, 2 woke up more than once due to symptoms ; 10 was the worst score.The daily score for an individual symptom score was the worst of the morning and evening scores on a particular day. If either the morning or evening score was missing for a symptom then the non-missing value was taken as the worst. A negative change indicates improvement. Only the scores for the 6 COPD symptoms (respiratory symptoms, cough, wheeze, production of sputum, sputum color, and breathlessness) were used to derive the total symptom score
Time frame: Baseline, 26 Weeks
Number of Patients With Adverse Events, Serious Adverse Events and Death
This endpoint reports patients affected by any adverse events (AE), serious adverse events (SAE) and death. Only treatment emergent AE, SAE, deaths are reported for this endpoint.
Time frame: 26 Weeks
| Milestone | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Started | 388 | 388 |
| Completed | 362 | 363 |
| Not completed | 26 | 25 |
| Withdrew: Patient decision | 14 | 10 |
| Withdrew: Adverse event | 8 | 8 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Noncompliance with study treatment | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Protocol deviation | 0 | 1 |
Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1 at Week 12. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.
| Liters | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 | 0.092 ± 0.0126 | 0.059 ± 0.0125 |
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 12 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.
| Liters | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| AUC (0-12 hour) | 0.136 ± 0.0119 | 0.106 ± 0.0118 |
| AUC (0-24 hour) | 0.085 ± 0.0121 | 0.043 ± 0.0120 |
| AUC (12-24 hour) | 0.035 ± 0.0125 | -0.019 ± 0.0124 |
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for 0-12 hour, post dosing at Day 1 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.
| Liters | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Change From Baseline in Area Under The Curve (AUC 0-12 Hour) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at Day 1 | 0.143 ± 0.0089 | 0.139 ± 0.0087 |
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 26 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.
| Liters | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| AUC (0-12 hour) | 0.123 ± 0.0121 | 0.091 ± 0.0120 |
| AUC (0-24 hour) | 0.076 ± 0.0122 | 0.030 ± 0.0121 |
| AUC (12-24 hour) | 0.032 ± 0.0127 | -0.028 ± 0.0126 |
The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: * Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity * Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness * Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. Higher values corresponded to greater impairment of health status.
| score on a scale | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Change from Baseline to WK 12 | -5.320 ± 0.6000 | -3.563 ± 0.5987 |
| Change from Baseline to WK 26 | -6.587 ± 0.6543 | -4.644 ± 0.6527 |
The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: * Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity * Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness * Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. A clinically significant improvement is defined as ≥ 4 unit improvement from baseline score (a decrease of ≥ 4).
| percentage of patients | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Change from Baseline to WK 12 | 54.5 | 46.9 |
| Change from Baseline to WK 26 | 59.4 | 49.6 |
Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score.
| score on a scale | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Change from Baseline to WK 12 | 1.346 ± 0.1430 | 0.849 ± 0.1433 |
| Change from Baseline to WK 26 | 1.523 ± 0.1539 | 1.170 ± 0.1534 |
Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. Clinically important improvement indicates ≥ 1 unit in the TDI focal score at Weeks 12 and 26 in comparison to BDI focal score (an increase of ≥ 1).
| Percentage of patients | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Change from Baseline to WK 12 | 56.9 | 52.0 |
| Change from Baseline to WK 26 | 61.1 | 54.6 |
Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.
| Liters | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Change from baseline to Day 1 | 0.119 ± 0.0099 | 0.070 ± 0.0097 |
| Change from baseline to Week 26 | 0.104 ± 0.0129 | 0.056 ± 0.0128 |
Mixed model for repeated measures was used to analyze change from baseline in FVC. Baseline FVC is defined as the average of the -45 min and -15 min FVC values taken on Day 1 prior to first dose.
| Liters | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Day 183/-45 min: | 0.079 ± 0.0195 | 0.025 ± 0.0192 |
| Day 183/-15 min: | 0.102 ± 0.0193 | 0.029 ± 0.0191 |
| Day 183/5 min: | 0.159 ± 0.0194 | 0.085 ± 0.0194 |
| Day 183/15 min: | 0.177 ± 0.0195 | 0.132 ± 0.0195 |
| Day 183/30 min: | 0.194 ± 0.0192 | 0.144 ± 0.0191 |
| Day 183/1 h: | 0.190 ± 0.0194 | 0.154 ± 0.0192 |
| Day 183/2 h | 0.229 ± 0.0193 | 0.200 ± 0.0191 |
| Day 183/3 h: | 0.229 ± 0.0197 | 0.186 ± 0.0192 |
| Day 183/4 h: | 0.216 ± 0.0194 | 0.169 ± 0.0191 |
| Day 183/6 h | 0.146 ± 0.0196 | 0.116 ± 0.0191 |
| Day 183/8 h | 0.137 ± 0.0195 | 0.085 ± 0.0193 |
| Day 183/10 h | 0.071 ± 0.0198 | 0.039 ± 0.0191 |
| Day 183/12 h | 0.041 ± 0.0200 | 0.026 ± 0.0196 |
| Day 183/13 h | 0.096 ± 0.0199 | 0.004 ± 0.0197 |
| Day 184/16 h | -0.014 ± 0.0207 | -0.081 ± 0.0206 |
| Day 184/22 h | -0.036 ± 0.0198 | -0.076 ± 0.0195 |
| Day 184/23 h 15 min | 0.075 ± 0.0201 | 0.031 ± 0.0194 |
| Day 184/23 h 45 min | 0.129 ± 0.0197 | 0.077 ± 0.0196 |
Mixed model for repeated measures was used to analyze change from baseline in IC.
| Liters | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Day 183/-20 min | 0.094 ± 0.0221 | 0.054 ± 0.0221 |
| Day 183/25 min | 0.181 ± 0.0224 | 0.173 ± 0.0215 |
| Day 183/1 h 55 min | 0.193 ± 0.0223 | 0.171 ± 0.0218 |
| Day 183/3 h 55 min | 0.163 ± 0.0226 | 0.159 ± 0.0221 |
| Day 183/7 h 55 min | 0.108 ± 0.0228 | 0.110 ± 0.0222 |
| Day 183/11 h 55 min | 0.042 ± 0.0229 | 0.030 ± 0.0218 |
| Day 184/23 h 40 min | 0.045 ± 0.0233 | 0.062 ± 0.0224 |
Mixed model for repeated measures was used to analyze change from baseline in FEV1. Baseline FEV1 is defined as the average of the -45 min and -15 min FEV1 values taken on Day 1 prior to first dose.
| Liters | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Day 183/-45 min | 0.058 ± 0.0120 | 0.012 ± 0.0119 |
| Day 183/-15 min | 0.086 ± 0.0119 | 0.034 ± 0.0118 |
| Day 183/5 min | 0.111 ± 0.0120 | 0.070 ± 0.0119 |
| Day 183/15 min | 0.145 ± 0.0120 | 0.106 ± 0.0120 |
| Day 183/30 min | 0.155 ± 0.0118 | 0.122 ± 0.0118 |
| Day 183/1 h | 0.158 ± 0.0120 | 0.132 ± 0.0118 |
| Day 183/2 h | 0.194 ± 0.0119 | 0.163 ± 0.0118 |
| Day 183/3 h | 0.179 ± 0.0121 | 0.154 ± 0.0118 |
| Day 183/4 h | 0.166 ± 0.0120 | 0.132 ± 0.0118 |
| Day 183/6 h | 0.110 ± 0.0121 | 0.080 ± 0.0118 |
| Day 183/8 h | 0.118 ± 0.0121 | 0.064 ± 0.0119 |
| Day 183/10 h | 0.067 ± 0.0122 | 0.038 ± 0.0118 |
| Day 183/12 h | 0.056 ± 0.0123 | 0.024 ± 0.0121 |
| Day 183/13 h | 0.093 ± 0.0123 | 0.000 ± 0.0121 |
| Day 184/16 h | -0.001 ± 0.0128 | -0.063 ± 0.0127 |
| Day 184/22 h | -0.012 ± 0.0122 | -0.043 ± 0.0120 |
| Day 184/23 h 15 min | 0.076 ± 0.0124 | 0.032 ± 0.0120 |
| Day 184/23 h 45 min | 0.122 ± 0.0122 | 0.067 ± 0.0121 |
Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. change from baseline in percentage of days without rescue medication usage over 26 weeks was analyzed.
| percentage of days | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Change From Baseline in the Percentage of Days With no Rescue Medication Use Over the 26 Weeks | 16.574 ± 2.3519 | 15.363 ± 2.3927 |
Patients reported symptoms by using an electronic diary. The mean daily total symptom score, the mean morning symptom score and the mean evening symptom score were calculated for each patient over 26 weeks. Each symptom measured in a numeric rating scale of 0-10; 0 indicates no symptom and 10 indicates severe symptom. 0 is no waking due to symptoms, 1 woke up once, 2 woke up more than once due to symptoms ; 10 was the worst score.The daily score for an individual symptom score was the worst of the morning and evening scores on a particular day. If either the morning or evening score was missing for a symptom then the non-missing value was taken as the worst. A negative change indicates improvement. Only the scores for the 6 COPD symptoms (respiratory symptoms, cough, wheeze, production of sputum, sputum color, and breathlessness) were used to derive the total symptom score
| score on a scale | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Change in mean daily | -1.336 ± 0.1141 | -1.107 ± 0.1160 |
| Change in mean morning | -1.032 ± 0.1304 | -0.828 ± 0.1318 |
| Change in mean evening | -1.205 ± 0.1141 | -1.056 ± 0.1152 |
This endpoint reports patients affected by any adverse events (AE), serious adverse events (SAE) and death. Only treatment emergent AE, SAE, deaths are reported for this endpoint.
| Count of Participants | NVA237 Twice Daily | NVA237 Once Daily |
|---|---|---|
| Patients with at least one AE | 203 | 224 |
| Patients with at least one SAE | 33 | 30 |
| Death | 1 | 1 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 22 mcg b.i.d. | 1/388 (0.3%) | 33/388 (8.5%) | 126/388 (32.5%) |
| NVA237 44 mcg o.d. | 2/388 (0.5%) | 30/388 (7.7%) | 152/388 (39.2%) |
| Event | NVA237 22 mcg b.i.d. | NVA237 44 mcg o.d. |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 11/388 | 15/388 |
| PneumoniaInfections and infestations | 3/388 | 4/388 |
| Atrial fibrillationCardiac disorders | 3/388 | 2/388 |
| Angina unstableCardiac disorders | 2/388 | 0/388 |
| Bronchial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/388 | 0/388 |
| SchizophreniaPsychiatric disorders | 2/388 | 0/388 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/388 | 0/388 |
| Atrial flutterCardiac disorders | 1/388 | 0/388 |
| Atrial tachycardiaCardiac disorders | 1/388 | 0/388 |
| Cardiac failure chronicCardiac disorders | 1/388 | 0/388 |
| Event | NVA237 22 mcg b.i.d. | NVA237 44 mcg o.d. |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 74/388 | 99/388 |
| NasopharyngitisInfections and infestations | 37/388 | 54/388 |
| HypertensionVascular disorders | 10/388 | 14/388 |
| BronchitisInfections and infestations | 10/388 | 3/388 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/388 | 2/388 |
| HeadacheNervous system disorders | 4/388 | 8/388 |
Randomized set
| Age, Continuous(years) | NVA237 Twice Daily | NVA237 Once Daily | Total |
|---|---|---|---|
| Mean | 63.2 ± 7.71 | 63.6 ± 7.66 | 63.4 ± 7.68 |
| Sex: Female, Male(Participants) | NVA237 Twice Daily | NVA237 Once Daily | Total |
|---|---|---|---|
| Female | 122 | 111 | 233 |
| Male | 266 | 277 | 543 |
Ran from Jun 2015 to primary completion in Nov 2016, 16 months.
Results were first posted in Aug 2019, 2 years 8 months after primary completion.
Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 16 months is close to that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →